Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study

Keyphrases

• 3-point 7%
• Active Ulcerative Colitis 100%
• Adult Age 7%
• Adverse Events 14%
• Anal Verge 7%
• Bleeding Score 7%
• Clinical Remission 7%
• Clinical Response 28%
• Concomitant Treatment 7%
• Corticosteroid Treatment 7%
• Disease Activity 7%
• Etrolizumab 100%
• Induction Period 7%
• Induction Studies 7%
• Integrin 7%
• Maintenance of Remission 7%
• Maintenance Phase 14%
• Maintenance Therapy 100%
• Mayo Clinic 21%
• Modified Intention-to-treat 7%
• Monoclonal Antibody 7%
• No Significant Difference 7%
• One Dose 7%
• Phase II Study 100%
• Placebo 28%
• Placebo Groups 42%
• Randomized Placebo-controlled Trial 100%
• Rectal Bleeding 28%
• Remission 21%
• Remission Status 7%
• Safety Signal 7%
• Serious Adverse Events 7%
• Stool Frequency 7%
• Treatment Assignment 7%
• Treatment Difference 7%
• Treatment Facilities 7%
• Treatment Group 7%
• Tumour Necrosis Factor Inhibitor (TNFi) 7%
• Ulcerative Colitis 14%

Medicine and Dentistry

• Adverse Event 21%
• Anal Verge 7%
• Corticosteroid Therapy 7%
• Disease 7%
• Disease Activity 7%
• Etrolizumab 100%
• Group Therapy 7%
• Gut 7%
• Immunosuppressant 7%
• Integrin 7%
• Intention-to-Treat Analysis 7%
• Maintenance Therapy 100%
• Monoclonal Antibody 7%
• Pamicogrel 7%
• Placebo 100%
• Rectal Bleeding 28%
• TNF Inhibitor 7%
• Ulcerative Colitis 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 21%
• Disease 7%
• Disease Activity 7%
• Etrolizumab 100%
• Immunosuppressive Agent 7%
• Integrin 7%
• Monoclonal Antibody 7%
• Pamicogrel 7%
• Placebo 100%
• Rectum Hemorrhage 28%
• Remission 42%
• Tumor Necrosis Factor Inhibitor 7%
• Ulcerative Colitis 100%